That’s how long it’s been since Tom Izzo last hoisted a national championship trophy and apparently, the last time he’s felt anything.

I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded versions of Ozempic and Wegovy. This approach is in response to ...

Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and ...

The Rams need defensive support in the competitive NFC. White isn't a star, but he's good and experienced enough to contribute and would likely be relatively cheap. Adding White wouldn't preclude the ...

Hims & Hers Health, Inc. (HIMS) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

Hims & Hers Health Inc (NYSE:HIMS) operates a telehealth platform that connects consumers to licensed healthcare professionals for personalized medical care and wellness products.

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...